A strategic partner actively using recombinant membrane proteins produced using the TetraExpress™ platform to support and accelerate a novel drug discovery program.
Tetragenetics and Crystal Bioscience are combining TetraExpress™ produced ion channels and expertise in avian immunology and novel screening technology to identify therapeutic antibodies generated in chickens. This partnership has yielded functionally inhibiting antibodies against the human voltage gated potassium channel, Kv1.3
Tetragenetics and argenx are combining human ion channels produced in TetraExpress™ and the diversity of the llama immune system with antibody engineering to develop therapeutic antibodies.
Theranyx is generating functional antibody fragments (Therabodies) targeting a number of human ion channels produced in the TetraExpress™ system.
One of our first partners for ion channel drug discovery. This relationship focuses on an exclusive license for one sodium channel. Amgen and TetraGenetics have concurrent antibody discovery programs underway, utilizing a variety of phylogenetically diverse animal systems.
An important partnership that includes up to 5 ion channel targets. TetraGenetics uses its proprietary TetraExpress® system to produce unique ion channel antigens for use by MedImmune in its novel antibody discovery programs.
A new collaboration funded by the National Institutes of Health (NIH) to use Tetrahymena for the production of G protein-coupled receptors (GPCR’s). These GPCR’s are implicated in many human diseases and have previously been very difficult to produce in traditional systems.
A collaboration with Cornell University to utilize and support a national Tetrahymena stock center funded by the National Institutes of Health (NIH).
US Dept of Agriculture
This collaboration has focused on the detailed study of ion channel protein function using advanced electro-physiology techniques and has validated the quality of TetraGenetics’ channels.